Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TXNRD1 | Q16881 | 18/20 | 1.00 |
| ▸ | GSR | P00390 | 3/20 | 1.00 |
| ▸ | VCAM1 | P19320 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22280243 | 0.82 | TXNRD1 (1.00) | TXNRD1GSRVCAM1 | |
| SCHEMBL22280495 | 0.82 | TXNRD1 (1.00) | TXNRD1GSR | |
| SCHEMBL20476782 | 0.82 | TXNRD1 (1.00) | TXNRD1GSR | |
| SCHEMBL8599154 | 0.76 | TXNRD1 (0.61) | TXNRD1GSRVCAM1 | |
| SCHEMBL7033755 | 0.75 | TXNRD1 (0.60) | TXNRD1GSRVCAM1 | |
| SCHEMBL8175466 | 0.74 | TXNRD1 (0.61) | TXNRD1GSR | |
| SCHEMBL22280581 | 0.73 | TXNRD1 (1.00) | TXNRD1GSR | |
| SCHEMBL18497232 | 0.72 | TXNRD1 (0.56) | TXNRD1GSRVCAM1 | |
| SCHEMBL11653146 | 0.72 | MAPT (0.58) | TXNRD1GSR | |
| SCHEMBL2362856 | 0.71 | TXNRD1 (0.54) | TXNRD1GSR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220119348-A1 | HYDROCARBYLSULFONYL-SUBSTITUTED PYRIDINES AND THEIR USE IN THE TREATMENT OF CANCER | OBLIQUE THERAPEUTICS AB (SE) | 2022-04-21 | — | — | US | disclosed |
| US-11161815-B2 | Hydrocarbylsulfonyl-substituted pyridines and their use in the treatment of cancer | OBLIQUE THERAPEUTICS AB (SE) | 2021-11-02 | — | — | US | disclosed |
| US-20210038577-A1 | THIOREDOXIN REDUCTASE INHIBITORS FOR USE IN THE TREATMENT OF CANCER | CINDA PHARMA AB (SE) | 2021-02-11 | — | — | US | disclosed |
| US-20200239417-A1 | HYDROCARBYLSULFONYL-SUBSTITUTED PYRIDINES AND THEIR USE IN THE TREATMENT OF CANCER | OBLIQUE THERAPEUTICS AB (SE) | 2020-07-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200239417-A1 | HYDROCARBYLSULFONYL-SUBSTITUTED PYRIDINES AND THEIR USE IN THE TREATMENT OF CANCER | HCCS, ABL1, IDH1 | TXNRD1 549/4885GSR 546/4885VCAM1 4422/4885 |
| US-20220119348-A1 | HYDROCARBYLSULFONYL-SUBSTITUTED PYRIDINES AND THEIR USE IN THE TREATMENT OF CANCER | HCCS, ABL1, IDH1 | TXNRD1 549/4885GSR 546/4885VCAM1 4422/4885 |
| US-11161815-B2 | Hydrocarbylsulfonyl-substituted pyridines and their use in the treatment of cancer | HCCS, ABL1, IDH1 | TXNRD1 549/4885GSR 546/4885VCAM1 4422/4885 |
| US-20210038577-A1 | THIOREDOXIN REDUCTASE INHIBITORS FOR USE IN THE TREATMENT OF CANCER | TXNRD3, TXNRD1, TXNRD2 | TXNRD1 2/4885GSR 12/4885VCAM1 1688/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.